Liver Cirrhosis Clinical Trial
Official title:
Evaluation of Prolonged-release Pirfenidone in Patients With Viral C Hepatitis, With Sustained Viral Response and Advanced Residual Liver Fibrosis. Potential Role of Epigenetics to Understand Therapeutic Changes (MINERVA).
Prolonged-Release Pirfenidone (PR-PFD) is an anti-fibrogenic and anti-inflammatory molecule used for the treatment of idiopathic pulmonary fibrosis (approved by FDA) and liver fibrosis (approved in Mexico by COFEPRIS). PFD effects are mediated in part through inhibition of TGFβ, TNFα, IL-1 and IL-6, along with NFκB activation down-regulation causing reduced TNFα and IFNγ levels. The aim of this protocol is to know if the epigenetic factors induced by PR-PFD have a regulatory role to understand the progression variants in liver fibrosis in a group of patients with viral hepatitis C, with a history of sustained viral response and advanced residual liver fibrosis. To assess the safety and efficacy of two daily doses of pirfenidone (KitosCell® LP), in patients with compensated liver cirrhosis.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | January 1, 2024 |
Est. primary completion date | December 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients with a history of Chronic Viral Hepatitis C, of all genotypes, demonstrated with previous studies (positive viral load). 2. History of treatment with direct acting antivirals (AAD). 3. Demonstration of negative viral load at least 6 months after completing treatment with AAD, considered as sustained viral response (SVR). 4. Fibrotest and / or Liver Elastography test with advanced liver fibrosis scores (F3-F4). 5. Verification of advanced liver fibrosis in a liver biopsy. 6. Patients with Child Pugh functional class A or B and in stable clinical conditions (without active variceal hemorrhage, ascites or refractory encephalopathy) with consumption of drugs at stable doses in at least 30 days. 7. Laboratory tests that confirm her condition and functional class, with results that, in the opinion of the main researcher, do not put the patient at risk: - Complete blood count, with hemoglobin values = 10 g / dL, leukocytes = 3,000 mL, platelets = 50,000 mL - Creatinine <1.8 mg / dL Exclusion Criteria: 1. Child Pugh functional class C (= 10 points) 2. Pregnancy and lactation. 3. History of known allergy or hypersensitivity to PFD. 4. Having participated in another clinical study in the 60 days prior to the start of this one. 5. Hospitalization within 30 days prior to the start of administration of the medication. 6. Co-existing liver pathology: alcohol cirrhosis, hemochromatosis, Wilson's disease, a-1-antitrypsin deficiency, amyloidosis, autoimmune hepatitis, and Primary Biliary Cholangitis). 7. Concomitant systemic infection including viral hepatitis B, HIV, as well as respiratory infections, urinary, digestive, cellulite, etc. 8. Serious concomitant conditions such as Heart Failure, Respiratory Failure and Chronic Kidney Failure. 9. Malignant neoplasms including hepatocellular carcinoma. Patients with basal cell carcinoma or those with malignancies with more than 5 years of inactivity may be considered for the study. 10. Decompensated diabetes mellitus (defined as that with fasting blood glucose values greater than 175 mg / dL and / or glycated hemoglobin greater than 8%). 11. Uncontrolled hypertension despite medications (defined as systolic values = 150 and diastolic values = 100 mmHg). 12. Patients with active alcohol intake in the last 6 months. 13. Use of drugs known as concomitant hepatoprotectors (ursodexosicolic acid, s-adenosyl-methionine, silymarin, among others). 14. Patients with treatment of CYP1A2 inhibitor drugs or other CYP isoenzymes such as: fluvoxamine, amiodarone, fluconazole, chloramphenicol, fluoxentine, paroxentine, ciprofloxacin, rifampin or propafenone, or other medicinal products that, in the opinion of the main investigator, may interfere with the study. 15. Any other clinical condition that in the opinion of the main investigator could compromise the safety and well-being of the patient or jeopardize the conduct of the study. |
Country | Name | City | State |
---|---|---|---|
Mexico | Institute for Molecular Biology in Medicine and Gene Therapy, CUCS, UdeG | Guadalajara | Jalisco |
Mexico | Hospital Central Militar | Mexico City |
Lead Sponsor | Collaborator |
---|---|
University of Guadalajara | Hospital Central Militar |
Mexico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Liver biopsy | Reduction of one unit in the METAVIR histological scale (F0-F4) | 12 months | |
Primary | Elastography | =30% reduction in the final Pascal score, compared to baseline. | 12 months | |
Secondary | Changes in the degree of methylation | of the following genes PPAR?, PPAR?, PPARa, TGFß1, Col1A1 and PDGFa in ccfDNA in DNA obtained by liver biopsy. | 12 months | |
Secondary | Changes in expression levels of miRNA's | Changes in expression levels of miR-122, miR192, miR-200a / b, miR-221/222, miR-34a, miR-16, miR-21, and miR-181b. | 12 months | |
Secondary | Transcriptome measurement in ccfRNA | Changes in transcriptome measurement in ccfRNA | 12 months | |
Secondary | Albumin and liver enzyme values | Albumin and liver enzyme values | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04533932 -
Endosonographic Shear Wave Elastography for Liver Stiffness
|
||
Not yet recruiting |
NCT06031740 -
A Comparison of Flexible Endoscopic Polidocanol Liquid and Foam Sclerotherapy in Cirrhotic Patients With Bleeding From Internal Hemorrhoids
|
N/A | |
Not yet recruiting |
NCT06026267 -
Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis
|
N/A | |
Not yet recruiting |
NCT06076330 -
Efficacy of 5% Albumin v/s Plasmalyte in Combination With 20% Albumin for Fluid Resuscitation in Cirrhosis With Sepsis Induced Hypotension
|
N/A | |
Enrolling by invitation |
NCT05055713 -
A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism
|
N/A | |
Recruiting |
NCT04578301 -
Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
|
||
Not yet recruiting |
NCT05515861 -
Evaluation of EUS in Preventing Rebleeding After Endoscopic Cyanoacrylate Injection for Gastric Varices
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Not yet recruiting |
NCT03623360 -
Functional MRI to Determine Severity of Cirrhosis
|
||
Not yet recruiting |
NCT02710227 -
Sleep Timing and Circadian Preferences in A Sample of Egyptian Patients With Hepatic Cirrhosis
|
N/A | |
Completed |
NCT02917408 -
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
|
||
Active, not recruiting |
NCT02551250 -
Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis
|
||
Recruiting |
NCT02239991 -
Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant
|
N/A | |
Enrolling by invitation |
NCT02256514 -
Open Label Trial of Immunotherapy for Advanced Liver Cancer
|
Phase 2 | |
Terminated |
NCT02311985 -
Comparison of Three Transfusion Strategies for Central Venous Catheterization in Cirrhotics: A Randomized Clinical Trial
|
N/A | |
Terminated |
NCT01937130 -
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
|
Phase 2 | |
Recruiting |
NCT01728688 -
Safety and Efficacy of Human Autologous Peripheral Blood Stem Cells for Treatment of HBV-related Liver Cirrhosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT01618890 -
Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding
|
Phase 3 | |
Recruiting |
NCT01728727 -
Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT01724697 -
Safety and Efficacy of Human Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis
|
Phase 1/Phase 2 |